Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Splenomegaly 1Primary Myelofibrosis 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Leukemia 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Squamous Cell 1Anus Neoplasms 1Anemia 1

Interventions

Cisplatin 139pembrolizumab 88Carboplatin 73Radiotherapy 71Cetuximab 69Docetaxel 58Paclitaxel 52Radiotherapy, Intensity-Modulated 43Fluorouracil 43Nivolumab 32Surgical Procedures, Operative 18Albumin-Bound Paclitaxel 15130-nm albumin-bound paclitaxel 15Radiation 14Drug Therapy 14tislelizumab 13Taxes 13durvalumab 12Magnetic Resonance Spectroscopy 12toripalimab 11camrelizumab 11Platinum 11Chemoradiotherapy 11Biopsy 11cemiplimab 10Radiosurgery 10Erlotinib Hydrochloride 10Capecitabine 10Specimen Handling 9Neoadjuvant Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Squamous Cell Carcinoma of Head and Neck × ON 01910 × Clear all
NCT01807546 2017-06-26

Oral Rigosertib for Squamous Cell Carcinoma

Traws Pharma, Inc.

Phase 2 Completed
64 enrolled
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Anus Neoplasms, Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡